Fingerprint
Dive into the research topics of 'Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability
James D. Berry, Sabrina Paganoni, Nazem Atassi, Eric A. Macklin, Namita Goyal, Michael Rivner, Ericka Simpson, Stanley Appel, Daniela L. Grasso, Nicte I. Mejia, Farrah Mateen, Alan Gill, Fernando Vieira, Valerie Tassinari, Steven Perrin
Research output: Contribution to journal › Article › peer-review
38
Scopus
citations